Abstract:

Aim: Cytoreductive surgery (CRS) applied together with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to prolong survival in advanced stage ovarian cancer. The aim of this study was to present the short-term results of patients with primary and recurrent advanced stage ovarian cancer applied with CRS+HIPEC in a single centre. Methods: A retrospective examination was made of 18 patients with a diagnosis of advanced stage ovarian cancer applied with CRS+HIPEC in a single centre between May 2019 and March 2020. A record was made for each patient of demographic data, CA125 values, peritoneal carcinomatosis index (PCI), completeness of cytoreduction score (CC), surgical procedures applied to the patient, complications, disease-free survival (DFS) and overall survivial (OS). Results: In the group with PCI ≥10, DFS was 18 months, and OS was 19 months, and the group with PCI ≤9, DFS and OS were found to be 20 months. No significant difference was determined between the two groups in respect of DFS and OS (p>0.05). In patients with CC0, DFS and OS were calculated as 20 months, and in those with CC1+CC2, DFS was 12 months and OS was 13.2 months. A statistically significant difference was determined between the two groups in respect of DFS and OS (p>0.05). Conclusion: The study results demonstrated that optimal CRS applied together with HIPEC to patients with advanced stage ovarian cancer prolonged survival. The operations of these patients should be performed by experienced surgical oncology and gynaecology oncology surgery specialists.

Keywords: